Feeds

Friends and families deal with drug trial fallout

Victims 'screamed'

Security for virtualized datacentres

Details continue to emerge of the London drug test that put six volunteers in a critical condition.

Speaking to the Mirror, Dolores Flanagan, aunt of 21-year-old Ryan Wilson, one of the men that reacted badly to the drug, said: "The family are in pieces. He's in the hands of God now."

The Sun got hold of one of the more fortunate participants in the trial, who seems to have been given a placebo. Raste Khan said: "Some screamed out that their heads felt like they were going to explode."

Late this afternoon, authorities at Northwick Park Hospital in London said the condition of four of the men is showing signs of improvement. A statement said: "The other two men remain critical and it could be a while until they show significant change."

Student David O'Donnell, 19, was due to take part in the next stage of testing of the drug in April at a higher dose. A friend of his took part in the trial and is seriously ill. O'Donnel told the BBC: "I am very worried about him indeed, but I had a message from my friends to say they have managed to get in contact with him."

The distressed girlfriend of one of the men said yesterday that he looked like "the Elephant Man". Northwick Park intensive care clinical director Ganesh Suntharalingam tried to calm fears: "These patients sometimes need a lot of fluid, and one result of that is severe but temporary swelling. This is distressing for relatives to see, but it does go away on recovery and it has no long-term effects."

The experimental drug TGN1412 administered to the six was aimed at combatting immunological diseases - chronic conditions like rheumatoid arthritis, multiple sclerosis and leukaemia. German firm Tegenero had contracted American firm Parexel to carry out the first human trials for the new therapy in Britain.

TGN1412 is designed to target rogue T-cells which cause these illnesses. In the trial it triggered a massive inflammatory response in the healthy human volunteers, despite passing animal testing without problems.

TeGenero says it has apologised to the sick men's families.

A TeGenero statement says: "The drug was developed in accordance with all regulatory and clinical guidelines and standards."

Parexel works as a contractor running testing of many new drugs. It agreed that all guidelines had been followed. Its testing programmes draw in cash-strapped students with offers of easy money. Parexel's website trumpets: "Paid time to yourself."

It's unclear if there will be any kind of compensation pay out.

In an open letter to the British Medical Journal back in February, University of London Professor Desmond Laurence criticised the unclear arrangements for compensation when drug trials go wrong.

He said documents covering drug trials were not written in plain language and therefore did not meet the legal requirement of fairness and openness under consumer law. He observed: "The cost of compensation for non-negligent harm falls upon the injured patients themselves."®

Security for virtualized datacentres

More from The Register

next story
Boffins who stare at goats: I do believe they’re SHRINKING
Alpine chamois being squashed by global warming
What's that STINK? Rosetta probe shoves nose under comet's tail
Rotten eggs, horse dung and almonds – yuck
Comet Siding Spring revealed as flying molehill
Hiding from this space pimple isn't going to do humanity's reputation any good
Kip Thorne explains how he created the black hole for Interstellar
Movie special effects project spawns academic papers on gravitational lensing
Experts brand LOHAN's squeaky-clean box
Phytosanitary treatment renders Vulture 2 crate fit for export
LONG ARM of the SAUR: Brachially gifted dino bone conundrum solved
Deinocheirus mirificus was a bit of a knuckle dragger
Moment of truth for LOHAN's servos: Our US allies are poised for final test flight
Will Vulture 2 freeze at altitude? Edge Research Lab to find out
prev story

Whitepapers

Why cloud backup?
Combining the latest advancements in disk-based backup with secure, integrated, cloud technologies offer organizations fast and assured recovery of their critical enterprise data.
A strategic approach to identity relationship management
ForgeRock commissioned Forrester to evaluate companies’ IAM practices and requirements when it comes to customer-facing scenarios versus employee-facing ones.
Security for virtualized datacentres
Legacy security solutions are inefficient due to the architectural differences between physical and virtual environments.
Reg Reader Research: SaaS based Email and Office Productivity Tools
Read this Reg reader report which provides advice and guidance for SMBs towards the use of SaaS based email and Office productivity tools.
New hybrid storage solutions
Tackling data challenges through emerging hybrid storage solutions that enable optimum database performance whilst managing costs and increasingly large data stores.